RT Journal Article
SR Electronic
T1 Impact of COVID-19 on Clinical Frailty Scale – a multicentre prospective cohort study
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP OA84
DO 10.1183/13993003.congress-2021.OA84
VO 58
IS suppl 65
A1 Guler, Sabina A.
A1 Müller, Ilena
A1 Mancinetti, Marco
A1 Bridevaux, Pierre-Olivier
A1 Brutsche, Marin
A1 Clarenbach, Christian
A1 Garzoni, Christian
A1 Lenoir, Alexandra
A1 Naccini, Bruno
A1 Ott, Sebastian R.
A1 Piquilloud, Lise
A1 Prella, Maura
A1 Que, Yok-Ai
A1 Soccal, Paola
A1 Von Garner, Christophe
A1 Geiser, Thomas
A1 Funke-Chambour, Manuela
YR 2021
UL http://erj.ersjournals.com/content/58/suppl_65/OA84.abstract
AB Background: The Clinical Frailty Scale (CFS) predicts short-term mortality in COVID-19, but the effect of COVID-19 on medium-term frailty is unknown.Objective: To estimate the impact of COVID-19 and factors associated with CFS at follow-up.Methods: Patients estimated their CFS before and 4 months after COVID-19. CFS ranges from 1-9 (very fit to terminally ill). The associations of 4-month post COVID-19 CFS with forced vital capacity (FVC), diffusion capacity for carbon monoxide (DLCO), 6-minute walk distance (6MWD), and dyspnea (modified Medical Research Council [mMRC]) were evaluated.Results: 132 survivors of COVID-19 (65% men) were included. Mean±SD age was 57±13 years. Change in CFS pre- to 4-month post-COVID-19 differed depending on the need for and kind of hospitalisation (Figure ). At follow-up 60 participants (45%) were vulnerable (CFS ≥3) and 9 (7%) frail (CFS ≥5). CFS correlated with FVC% (r=-0.36, p<0.0001), DLCO% (r=-0.33, p=0.0002), 6MWD (r=-0.39, p<0.0001), and mMRC (r=0.57, p<0.0001). These correlations remained significant in separate multivariable models adjusting for the confounders age, sex, mode of hospitalisation, and BMI, with the strongest association for mMRC (coefficient 0.09, p<0.0001, R2 0.42).Conclusions: COVID-19 accelerates frailty, particularly in patients with ICU hospitalisation. Dyspnea is the strongest determinant of 4-month post-COVID-19 frailty and should be addressed thoroughly.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, OA84.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).